The Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, presents its (unaudited) financial report for the first nine months and the third quarter ended 30 September 2017.
Today Pharming announced that since the release of its update regarding cashless and other warrant exercises and bond conversions on 10 August 2017, it has issued 12,548,663 new shares to holders of warrants who have exercised those warrants, and to holders of its ordinary convertible bonds due 2021 who have converted their Bonds into shares.
Today Pharming announced positive data from a clinical trial with the use of RUCONEST® [Recombinant Human C1 Esterase Inhibitor/ conestat alfa] for the treatment of hereditary angioedema (HAE) attacks in children.
Pharming Group N.V in association with HAEi, the international umbrella organization for the world’s Hereditary Angioedema (HAE) patient groups, announce the appointment of Inceptua Medicines Access as their new distribution partner for the “HAEi Global Access Program” (HAEi GAP).
Pharming announced today that it has concluded its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA).
A new analyst report from Van Leeuwenhoeck is published and available for download.
Today Pharming announced that since the release of its 2017 Half Year Report on 27 July 2017, it has issued 12,053,268 new shares to holders of warrants who have exercised those warrants, and to holders of its ordinary convertible bonds due 2021 who have converted their Bonds into shares.
Biotech company Pharming Group NV announces the analyst report completed by Scott R. Henry, CFA from Roth Capital Partners is published and available for download.
A new analyst report from Stifel Financial Corp. is published and available for download.
Pharming presents its (unaudited) financial report for the six months ended 30 June 2017.
